Want to see AU:ILA full AI Analyst Report?
ILA Stock Chart & Stats
AU$0.44
<AU$0.01(1.74%)
At close: 4:00 PM EST
AU$0.44
<AU$0.01(1.74%)
Day’s Range― - ―
52-Week RangeAU$0.15 - AU$0.63
Previous CloseN/A
Volume208.69K
Average Volume (3M)781.24K
Market Cap
AU$139.08M
Enterprise ValueAU$84.40M
Total Cash (Recent Filing)AU$6.87M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta-0.99
Next Earnings
Aug 27, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding295,916,700
10 Day Avg. Volume388,484
30 Day Avg. Volume781,243
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)3.39
Price to Sales (P/S)204.10
P/FCF Ratio-8.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.05
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet With Zero DebtIsland Pharmaceuticals’ zero-debt position and materially higher equity provide a durable solvency buffer for an early-stage biotech. Low financial leverage improves flexibility to pursue trials, partnerships or staged financings without immediate debt servicing pressure, supporting multi-month R&D execution.
Focused Antiviral R&D PipelineA concentrated small-molecule antiviral strategy and a lead candidate targeting mosquito-borne diseases creates a clear, defendable development path. Specialization can streamline clinical design, attract targeted partners and grants, and exploit unmet global needs in dengue/Zika, supporting sustained long-term value creation if trials progress.
Modest Improvement In Cash BurnReported modest improvement in cash burn versus the prior year suggests management has begun to tighten spending or prioritize higher-value activities. Progress on reducing negative cash flow, even if partial, extends runway and reduces near-term financing pressure, a durable operational improvement if sustained.
Bears Say
Sharp, Volatile Revenue DeclineA roughly 70% revenue drop signals weak commercial traction or one-off revenue loss, increasing reliance on development milestones and external funding. Persistent revenue volatility undermines internal cash generation, complicates long-term planning and reduces the firm's ability to self-fund R&D and scale operations over several months.
Deep And Persistent Net LossesSustained large net losses and negative margins indicate the company remains pre-commercial or failing to monetize assets. Continued operating deficits erode equity, pressure governance choices, and increase the probability of dilutive capital raises, constraining long-term shareholder returns absent clear clinical progress or new revenue sources.
Negative Operating Cash Flow And Funding DependenceMaterial negative operating cash flow creates an enduring financing requirement. Even with zero debt, recurrent cash shortfalls force reliance on equity raises, partnerships or grants; these routes can dilute shareholders or delay programs. This funding dependency is a structural risk for execution over the next several months.
Island Pharmaceuticals Ltd News
ILA FAQ
What was Island Pharmaceuticals Ltd’s price range in the past 12 months?
Island Pharmaceuticals Ltd lowest share price was AU$0.14 and its highest was AU$0.63 in the past 12 months.
What is Island Pharmaceuticals Ltd’s market cap?
Island Pharmaceuticals Ltd’s market cap is AU$139.08M.
When is Island Pharmaceuticals Ltd’s upcoming earnings report date?
Island Pharmaceuticals Ltd’s upcoming earnings report date is Aug 27, 2026 which is in 42 days.
How were Island Pharmaceuticals Ltd’s earnings last quarter?
Island Pharmaceuticals Ltd released its earnings results on Feb 25, 2026. The company reported -AU$0.019 earnings per share for the quarter, missing the consensus estimate of -AU$0.005 by -AU$0.014.
Is Island Pharmaceuticals Ltd overvalued?
According to Wall Street analysts Island Pharmaceuticals Ltd’s price is currently Overvalued.
Does Island Pharmaceuticals Ltd pay dividends?
Island Pharmaceuticals Ltd does not currently pay dividends.
What is Island Pharmaceuticals Ltd’s EPS estimate?
Island Pharmaceuticals Ltd’s EPS estimate is -0.01.
How many shares outstanding does Island Pharmaceuticals Ltd have?
Island Pharmaceuticals Ltd has 295,916,700 shares outstanding.
What happened to Island Pharmaceuticals Ltd’s price movement after its last earnings report?
Island Pharmaceuticals Ltd reported an EPS of -AU$0.019 in its last earnings report, missing expectations of -AU$0.005. Following the earnings report the stock price went up 1.408%.
Which hedge fund is a major shareholder of Island Pharmaceuticals Ltd?
Currently, no hedge funds are holding shares in AU:ILA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Island Pharmaceuticals Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:ILA Sentiment 100%
Sector Average 67%
Sector Average 67%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
100.00%
12-Months-Change
Fundamentals
Return on Equity
-100.58%
Trailing 12-Months
Asset Growth
86.01%
Trailing 12-Months
Company Description
Island Pharmaceuticals Ltd
Island Pharmaceuticals Limited functions as a pharmaceutical enterprise dedicated to drug discovery and repurposing, with a specific focus on creating preventative or therapeutic solutions for viral infections. Its lead therapeutic agent, ISLA-101, is currently under development for both preventing and treating dengue fever and other illnesses transmitted by mosquitoes. The company participates in various strategic collaborations, including a research partnership with Monash University to evaluate known molecules against host targets, and a research and development alliance with Griffith University aimed at screening for active antiviral compounds through a systematic repurposing approach. Additionally, Island Pharmaceuticals has a research agreement with Compounds Australia, providing access to an extensive drug library containing roughly 4,500 molecules for potential drug repurposing and pipeline enhancement. In anticipation of its ISLA-101 Phase II clinical study, the company has also established a cooperative research and development pact with the U.S. Army. Other key agreements include a supply contract with Catalent for the production of Fenretinide softgels for individuals participating in dengue fever trials, and the entitlement to reference the National Cancer Institute's Investigational New Drug (IND) application for ISLA-101. The company, founded in 2017, is based in Camberwell, Australia.
Technical Analysis
Actinogen Medical
―
Paradigm Biopharmaceuticals
―
Immutep Ltd
―
Dimerix Limited
―
Recce Pharmaceuticals Ltd.
―